Impact of Inflation Reduction Act on Shingles Vaccine Uptake

Study Overview

A study led by Dima Qato from USC Mann School of Pharmacy evaluated the impact of Inflation Reduction Act (IRA) on shingles vaccine uptake among older adults. The IRA aimed to reduce healthcare costs by eliminating patient out-of-pocket costs for certain medications covered by Medicare Part D.

Research Findings

Published in JAMA: The Journal of the American Medical Association, the study revealed a 46% increase in shingles vaccinations covered by Part D after the implementation of the IRA policy in January 2023.

Significance of Shingles Vaccine

Shingles vaccine is recommended for adults aged 50 and above due to the increased risk of shingles, a viral infection that can lead to postherpetic neuralgia. The study compared vaccination rates between Medicare Part D and private insurance.

Policy Impact

According to Qato, policies like the IRA play a crucial role in improving access to essential medications and preventive services like vaccinations. Lowering patient out-of-pocket costs can enhance equity, access, and overall health outcomes.

Future Implications

While the study used data from retail pharmacies, further research is needed to assess the IRA’s impact on vaccination rate disparities. Evaluating equity in access to vaccinations is essential to ensure policies like the IRA benefit all populations.

Study Authors

Co-authors of the study include John A. Romley and Rebecca Myerson from USC Mann School, along with Dana Goldman from USC Price School. The research was conducted in collaboration with the Schaeffer Center for Health Policy & Economics.